1.85
price up icon2.21%   0.04
after-market Dopo l'orario di chiusura: 1.82 -0.03 -1.62%
loading
Precedente Chiudi:
$1.81
Aprire:
$1.78
Volume 24 ore:
709.14K
Relative Volume:
0.50
Capitalizzazione di mercato:
$120.63M
Reddito:
-
Utile/perdita netta:
$-117.50M
Rapporto P/E:
-0.7708
EPS:
-2.4
Flusso di cassa netto:
$-114.31M
1 W Prestazione:
+8.82%
1M Prestazione:
+23.33%
6M Prestazione:
-56.16%
1 anno Prestazione:
-74.62%
Intervallo 1D:
Value
$1.78
$1.95
Intervallo di 1 settimana:
Value
$1.6706
$1.95
Portata 52W:
Value
$1.31
$8.33

Nkarta Inc Stock (NKTX) Company Profile

Name
Nome
Nkarta Inc
Name
Telefono
(925) 407-1049
Name
Indirizzo
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Dipendente
157
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
NKTX's Discussions on Twitter

Confronta NKTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NKTX
Nkarta Inc
1.85 120.63M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-09 Iniziato Rodman & Renshaw Buy
2024-08-14 Aggiornamento Raymond James Outperform → Strong Buy
2024-03-22 Downgrade Raymond James Strong Buy → Outperform
2022-12-22 Downgrade Oppenheimer Outperform → Perform
2022-10-10 Iniziato Canaccord Genuity Buy
2022-07-28 Iniziato Needham Buy
2022-07-18 Iniziato SVB Leerink Outperform
2022-03-11 Iniziato Raymond James Outperform
2022-03-08 Iniziato H.C. Wainwright Buy
2022-01-06 Iniziato William Blair Outperform
2021-11-18 Iniziato SMBC Nikko Outperform
2021-07-16 Iniziato Oppenheimer Outperform
2020-08-04 Iniziato Cowen Outperform
2020-08-04 Iniziato Evercore ISI Outperform
2020-08-04 Iniziato Mizuho Buy
2020-08-04 Iniziato Stifel Buy
Mostra tutto

Nkarta Inc Borsa (NKTX) Ultime notizie

pulisher
02:21 AM

Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World

02:21 AM
pulisher
Apr 18, 2025

JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 16, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Nkarta (NKTX) Upgraded to Buy: Here's Why - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Apr 11, 2025
pulisher
Apr 11, 2025

Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 11, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Nkarta to Participate in an April Investor Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter

Apr 01, 2025
pulisher
Mar 31, 2025

Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025
pulisher
Mar 27, 2025

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech

Mar 27, 2025
pulisher
Mar 27, 2025

Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Announces Major Restructuring and Leadership Changes - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

TD Cowen Keeps Their Buy Rating on Nkarta (NKTX) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 21, 2025

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Mar 19, 2025
pulisher
Mar 17, 2025

Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView

Mar 17, 2025

Nkarta Inc Azioni (NKTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):